Cancer remains one of the most significant healthcare challenges facing the world today. According to the World Health Organization, cancer accounted for nearly 10 million deaths in 2024, representing almost one in every six deaths globally. In the same year, some of the most commonly diagnosed cancers included lung, breast, colorectal and prostate cancers, reflecting the scale and diversity of the disease burden.
But the challenge of cancer extends far beyond the number of cases.
Cancer is not a single disease. It represents a large group of diseases, each with different biological characteristics, patterns of progression and treatment requirements. Treatment may involve surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapies or combinations of different approaches, depending on the cancer and the individual patient.
This complexity creates a demanding requirement for the pharmaceutical industry: oncology medicines need to be available across a broad spectrum of molecules, therapeutic applications and dosage forms, while maintaining stringent standards of quality and consistency.
Why Oncology Requires Dedicated Pharmaceutical Expertise
Oncology pharmaceutical manufacturing requires capabilities that go beyond those of a broad pharmaceutical portfolio.
The oncology segment encompasses established chemotherapy medicines as well as newer targeted therapies and other advanced treatments. Healthcare systems may require medicines in different formulations depending on the therapeutic requirement — from oral tablets and capsules to injectable and specialised formulations.
At the same time, the importance of quality becomes particularly significant. Pharmaceutical manufacturers must maintain controlled processes, validated systems, appropriate testing and stringent quality checks throughout manufacturing and release.
This is why specialised oncology pharmaceutical companies play an important role in strengthening the availability of cancer medicines.
A dedicated oncology focus allows pharmaceutical companies to build deeper capabilities around oncology molecules, formulations, manufacturing processes, regulatory requirements and supply networks.
At Zuvius Lifesciences, oncology is not simply one segment of our business. It is the foundation around which we have built our pharmaceutical portfolio, capabilities and global presence.
Zuvius Lifesciences: An Oncology-Focused Pharmaceutical Company
We have built Zuvius Lifesciences with a clear focus on oncology and the objective of making a broad range of cancer medicines accessible across healthcare markets.
Our journey in healthcare began with medical distribution, and over the years our focus expanded into oncology. We subsequently established Zuvius Lifesciences with oncology as a core focus and continued investing in the development of our oncology portfolio and capabilities.
This long-term focus has shaped the way we approach our portfolio today — not as a collection of individual products, but as a broad oncology platform designed to address diverse therapeutic requirements.
Our experience across oncology has enabled us to expand our product basket, strengthen our manufacturing and quality capabilities, and establish a growing network across India and international markets.
A Wide Range of Anticancer Drugs
At Zuvius Lifesciences, we are the manufacturer of the widest range of anticancer drugs in the world, with 250+ SKUs covering multiple oncology molecules and dosage forms.
Our portfolio includes medicines across a broad spectrum of oncology requirements. Some examples include Afatinib, Azacitidine, Acalabrutinib, Cabozantinib, Olaparib, Palbociclib, Pomalidomide, Sunitinib, Goserelin, Fludarabine Phosphate, Regorafenib and Topotecan, among others.
The breadth of this portfolio reflects the diverse pharmaceutical requirements within oncology. Different cancers, disease stages and therapeutic strategies require access to different molecules and treatment options.
Our focus, therefore, has been to develop a portfolio that brings together established oncology medicines and newer therapeutic molecules under a single specialised oncology platform.
This breadth is one of the defining characteristics of Zuvius.
Multiple Dosage Forms for Oncology Medicines
Dosage-form capability is an important part of pharmaceutical manufacturing. Different oncology medicines may require different formulations and routes of administration.
The broader Zuvius portfolio includes 250+ SKUs across:
- Tablets
- Capsules
- Liquid injectables
- Lyophilized injectables
- Pre-filled syringes
This combination of oral and injectable formulations provides coverage across multiple pharmaceutical dosage forms and supports the company's position among specialised oncology products manufacturers in India.
It is also relevant for organisations specifically looking for an oncology injections manufacturer in India, where injectable formulation capabilities form an important part of the supply requirement.
Quality and Regulatory Standards
Quality and regulatory compliance are fundamental to pharmaceutical manufacturing, particularly when medicines are supplied across different markets.
Zuvius's official accreditation profile includes references to EU GMP, US FDA, WHO and PIC/S, alongside other market-specific accreditations including Anvisa, Cofepris and Invima.
For pharmaceutical buyers, these credentials form part of the broader evaluation of an oncology pharmaceutical company, together with product documentation, applicable registrations, specifications and market requirements.
The specific certification or regulatory approval applicable to a product or market can vary and should be assessed against the relevant regulatory documentation.
Domestic and International Reach
Manufacturing is only one part of the pharmaceutical supply chain. Distribution and market access are equally important for maintaining reliable medicine availability.
Zuvius has a domestic network spanning 28 states and 8 Union Territories, with a reach across 15,000+ hospitals and clinics supported by 100+ distribution partners.
Our international presence extends across 51+ countries and 6 continents, supported by 50+ global partners.
This combination of domestic distribution and international market presence has helped build Zuvius as an oncology-focused pharmaceutical business serving healthcare markets beyond India.
Growing Alongside the Oncology Industry
The oncology pharmaceutical industry continues to evolve as research improves the understanding of cancer biology and treatment.
Established medicines remain an important part of cancer care, while targeted and other specialised therapies continue to expand treatment options for certain cancers. This changing landscape creates a continuing need for pharmaceutical companies to strengthen their portfolios, formulation capabilities, quality systems and supply networks.
At Zuvius, we continue to strengthen our oncology portfolio, formulation capabilities and presence across domestic and international markets alongside these developments.
Our long-term focus on oncology, combined with a broad portfolio and international presence, provides a foundation for continued participation in the evolving pharmaceutical landscape.
Frequently Asked Questions
What makes Zuvius Lifesciences an oncology-focused pharmaceutical company?
At Zuvius Lifesciences, oncology is the core of our pharmaceutical business. We have developed a specialised portfolio of 250+ SKUs covering multiple anticancer molecules and dosage forms, supported by dedicated quality and manufacturing capabilities.
How many oncology products does Zuvius Lifesciences have?
We have 250+ SKUs across our oncology portfolio, covering tablets, capsules, liquid injectables, lyophilized injectables and pre-filled syringes.
What types of oncology medicines does Zuvius manufacture?
Our portfolio covers a broad range of oncology molecules, including medicines based on Afatinib, Acalabrutinib, Azacitidine, Cabozantinib and Olaparib, among others.
Does Zuvius Lifesciences serve international markets?
Yes. Our oncology products currently reach 51+ countries across 6 continents, supported by 50+ global partners.
What dosage forms are available in the Zuvius oncology portfolio?
Our portfolio includes tablets, capsules, liquid injectables, lyophilized injectables and pre-filled syringes, allowing us to address different formulation requirements within oncology.
How does Zuvius approach pharmaceutical quality?
Our Quality Assurance and Quality Control systems cover validation, documentation control, in-process checks, stability studies, batch release, complaint investigation and other quality processes designed to maintain consistent pharmaceutical standards.
Conclusion
Cancer is a complex and growing global healthcare challenge, creating an ongoing need for specialised pharmaceutical companies that can support the availability of a broad range of quality oncology medicines. Meeting this need requires more than individual products — it requires oncology expertise, portfolio depth, diverse formulations, robust quality systems and the ability to reach healthcare markets at scale.
At Zuvius Lifesciences, oncology is at the heart of everything we do. We have built a portfolio of 250+ oncology SKUs across multiple dosage forms, supported by established quality systems and a growing network across India and international markets.
With a presence across 28 states and 8 Union Territories in India, and 51+ countries globally, we continue to expand our capabilities and strengthen our reach in oncology.
Our vision is to build a globally recognised oncology pharmaceutical company from India, expanding access to a wide range of quality anticancer medicines for healthcare markets around the world.